Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia

Joshua A. Sonnen, Kathleen S. Montine, Joseph F. Quinn, John C.S. Breitner, Thomas J. Montine

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Given the magnitude of the public health problem of dementia in the elderly, there is a pressing need for research, development, and timely application of biomarkers that will identify latent and prodromal illness as well as dementia. Although identification of risk factors and neuroimaging measures will remain key to these efforts, this review focuses on recent progress in the discovery, validation, and standardization of cerebrospinal fluid (CSF) biomarkers, small molecules and macromolecules whose CSF concentration can aid in diagnosis at different stages of disease as well as in assessment of disease progression and response to therapeutics. A multimodal approach that brings independent information from risk factor assessment, neuroimaging, and biomarkers may soon guide physicians in the early diagnosis and management of cognitive impairment in the elderly.

Original languageEnglish (US)
Pages (from-to)301-309
Number of pages9
JournalJournal of Alzheimer's Disease
Issue number1
StatePublished - 2010


  • Alzheimer's disease
  • Biomarkers
  • Cerebrospinal fluid
  • Lewy body disease
  • Vascular cognitive impairment

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health


Dive into the research topics of 'Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia'. Together they form a unique fingerprint.

Cite this